Trinucleotide Cap Analogs for mRNA Translation Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mRNA molecules used in in vivo applications face challenges in maintaining effective Cap structures for translation efficiency and often cause adverse immune responses due to high levels of double-stranded RNA (dsRNA), leading to reduced tolerability in subjects.
Innovation Solution
Development of trinucleotide cap analogs with reduced dsRNA content, which are administered at lower doses to enhance translation efficiency and improve tolerability by minimizing dsRNA-induced immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard Cap structures are used in mRNA molecules, then template activity for protein synthesis is maintained, but translation efficiency is suboptimal and adverse immune responses occur due to high dsRNA levels
Solution Approach 1:
The patent modifies the chemical parameters of the Cap structure by introducing 2′-O-methyl modifications at specific positions (N34, N35, N36) of the trinucleotide sequence. These parameter changes alter the conformational properties and chemical stability of the Cap, reducing its ability to form immunogenic dsRNA structures while preserving its function as a translation initiation signal. The modified Cap analogs maintain template activity but significantly reduce adverse immune responses.
2Productivity
If mRNA dosage is increased to improve therapeutic effect, then translation efficiency may improve, but tolerability decreases due to enhanced immune responses
Solution Approach 1:
By modifying the Cap structure parameters (2′-O-methyl modifications), the patent reduces the immunogenicity of the mRNA molecule. This allows therapeutic doses to be increased to improve productivity/therapeutic effect without proportionally increasing immune responses and reducing tolerability. The modified Cap enables higher dosing with acceptable tolerability profiles.
3Duration of action of stationary object
If conventional Cap structures are used, then mRNA stability is maintained, but translation efficiency is not optimized
Solution Approach 1:
The patent introduces specific 2′-O-methyl modifications at positions N34, N35, and N36 of the Cap trinucleotide sequence. These parameter changes optimize the balance between stability and translation efficiency by enhancing recognition by eukaryotic initiation factor 4E (eIF4E) while maintaining protection against 5′-exonuclease degradation. The modified Cap structures demonstrate improved translation efficiency compared to conventional Caps while preserving mRNA stability.
Data Source
AI summary
Described herein are novel trinucleotide cap analogs and methods of making and using the same. Also described herein is an RNA molecule comprising a 5′-cap, wherein the 5′-cap includes a trinucleotide cap analog as described herein. Methods of inducing a therapeutic effect in a 5 subject are also described herein, the methods including a step of administering to the subject an RNA molecule including the trinucleotide cap analog.